Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Neoplasma Vol.68, No.6, p.1283–1291, 2021 |
||
Title: A metabolomic signature of FIGO stage I and II endometrial cancer | ||
Author: Mingli Gu, Xin Chen, Yi Sun, Linguo Wan, Huizhen Shu, Cheng Qian | ||
Abstract: Endometrial cancer (EC) is a malignant tumor of the female reproductive tract. Due to its rapid growth and invasiveness, EC is currently the only gynecological neoplasm with rising incidence and mortality rates. It is of great significance to explore the metabolomics signature of stage I and II EC for the diagnosis and treatment. A mass spectrometry-based untargeted metabolomics approach was used to explore preoperative serum metabolites in the normal and stage I and II EC patients. The metabolites were mapped to the Ingenuity pathway analysis (IPA) database to determine the potential biomarkers and metabolic pathways that differ between EC patients and healthy controls. The top analysis-ready molecules of upregulated D-glucose thiamine and downregulated cholesterol, arachidonic acid, palmitic acid, oleic acid, stearic acid, linoleic acid may be the most related metabolites. These potential biomarkers have essential functions in regulating vital metabolic pathways associated with stage I and II EC. Additionally, our pathway analysis revealed five significantly related pathways according to the metabolite differentials. Finally, the disease and function prediction of the initial pathway analysis suggested that small molecule biochemistry, lipid metabolism, and organismal injury and abnormalities were associated with EC cases. Over 25 metabolites were differentially expressed in stage I and II EC. In addition, the six most significant metabolites were related to stage I and stage II EC cases. Ingenuity pathway analysis revealed potential biomarkers and metabolic pathways revolved to EC. In this paper, candidate endogenous biomarkers were defined as the basis for disease diagnosis and individualized treatment monitoring and revealed the mechanism of EC occurrence and development. |
||
Keywords: endometrial cancer; metabolomics; stage I and II; potential biomarkers; mass spectrometry | ||
Published online: 25-Oct-2021 | ||
Year: 2021, Volume: 68, Issue: 6 | Page From: 1283, Page To: 1291 | |
doi:10.4149/neo_2021_210306N288 |
||
|
download file |
|